Literature DB >> 11086089

The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses.

S M Varga1, E L Wissinger, T J Braciale.   

Abstract

BALB/c mice immunized with a vaccinia virus expressing the attachment (G) glycoprotein of respiratory syncytial virus (RSV) develop a virus-specific CD4(+) T cell response that consists of a mixture of Th1 and Th2 CD4(+) T cells following intranasal infection with live RSV. Recent work has shown that both Th1 and Th2 CD4(+) T cells are elicited to a single region comprising aa 183-197 of the G protein. To more precisely define the CD4(+) T cell epitope(s) contained within this region, we created a panel of amino- and carboxyl-terminal truncated as well as single alanine-substituted peptides spanning aa 183-197. These peptides were used to examine the ex vivo cytokine response of memory effector CD4(+) T cells infiltrating the lungs of G-primed RSV-infected mice. Analysis of lung-derived memory effector CD4(+) T cells using intracellular cytokine staining and/or ELISA of effector T cell culture supernatants revealed a single I-E(d)-restricted CD4(+) T cell epitope with a core sequence mapping to aa 185-193. In addition, we examined the T cell repertoire of the RSV G peptide-specific CD4(+) T cells and show that the CD4(+) T cells directed to this single immunodominant G epitope use a restricted range of TCR Vss genes and predominantly express Vss14 TCR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086089     DOI: 10.4049/jimmunol.165.11.6487

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

Review 1.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

2.  Effects of alveolar macrophage depletion on liposomal vaccine protection against respiratory syncytial virus (RSV).

Authors:  A Benoit; Y Huang; J Proctor; G Rowden; R Anderson
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.

Authors:  Luis Martinez-Sobrido; Negin Gitiban; Ana Fernandez-Sesma; Jerome Cros; Sara E Mertz; Nancy A Jewell; Sue Hammond; Emilio Flano; Russell K Durbin; Adolfo García-Sastre; Joan E Durbin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 4.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

5.  The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Yu-Jin Jung; Subbiah Jeeva; Young-Man Kwon; Baik Lin Seong; Sang Moo Kang
Journal:  Antiviral Res       Date:  2019-05-28       Impact factor: 5.970

6.  A critical role of Gas6/Axl signal in allergic airway responses during RSV vaccine-enhanced disease.

Authors:  Takehiko Shibata; Manabu Ato
Journal:  Immunol Cell Biol       Date:  2017-07-19       Impact factor: 5.126

7.  Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.

Authors:  Helene Plotnicky-Gilquin; Dominique Cyblat-Chanal; Jean-Pierre Aubry; Thierry Champion; Alain Beck; Thien Nguyen; Jean-Yves Bonnefoy; Nathalie Corvaïa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry.

Authors:  Whitney W Stevens; Taeg S Kim; Lindsey M Pujanauski; Xueli Hao; Thomas J Braciale
Journal:  J Immunol Methods       Date:  2007-08-08       Impact factor: 2.303

10.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.